Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Trial

Autor: Michael W.A. Chu, Marc Ruel, Allen Graeve, Marc W. Gerdisch, Ralph J. Damiano, Robert L. Smith, William Brent Keeling, Michael A. Wait, Robert C. Hagberg, Reed D. Quinn, Gulshan K. Sethi, Rosario Floridia, Christopher J. Barreiro, Andrew L. Pruitt, Kevin D. Accola, Francois Dagenais, Alan H. Markowitz, Jian Ye, Michael E. Sekela, Ryan Y. Tsuda, David A. Duncan, Daniel G. Swistel, Lacy E. Harville, Joseph J. DeRose, Eric J. Lehr, John H. Alexander, John D. Puskas, Chun 'Dan' Choi, Gosta Pettersson, Marc Gerdisch, O. Howard Frazier, Jeffrey Askew, Ralph Damiano, Andrew Pruitt, David Duncan, Romualdo Segurola, M. Fawaz Shoukfeh, Igor Gregoric, Steven Meyer, Michael Chu, Danny Chu, Robert Hagberg, Ryan Tsuda, Eric Kirker, Daniel Swistel, Lance Landvater, Christopher Barreiro, Brian Castlemain, Peter Tutuska, Reed Quinn, Thomas Beaver, Kevin Accola, Gulshan Sethi, Alan Graeve, David Liu, Michael Wait, Bryan Whitson, Lacy Harville, Joseph DeRose, Eric Lehr, Alan Markowitz, Michael Sekela, Robert Smith, Christian Shults, Prem Shekar, Vinay Badhwar

Publikováno v: The Annals of Thoracic Surgery. 115:929-938

Current guidelines recommend a target international normalized ratio (INR) range of 2.5 to 3.5 in patients with a mechanical mitral prosthesis. The Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT) Mitral randomized controlled nonin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763670537229909079559f61f12d6641
https://doi.org/10.1016/j.athoracsur.2022.12.031